Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cell- and Tissue-Based Therapy × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3 Other hematologic neoplasm 3 Gastrointestinal 3 Tumor-Agnostic 2 Lymphoid 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Gynecologic 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1 Erectile Dysfunction 1

Interventions

Docetaxel 365 pembrolizumab 282 Prednisone 252 enzalutamide 242 Gemcitabine 232 Magnetic Resonance Spectroscopy 231 Radiotherapy 228 Nivolumab 215 Abiraterone Acetate 184 Cisplatin 176 Leuprolide 170 Radiosurgery 169 Sunitinib 152 Carboplatin 142 Specimen Handling 134 Androgen Antagonists 130 bicalutamide 124 Goserelin 124 Ipilimumab 113 Paclitaxel 111 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 106 apalutamide 105 Cyclophosphamide 100 Everolimus 97 Sorafenib 95 Biopsy 95 cabozantinib 91 Bevacizumab 90 abiraterone 88 atezolizumab 86

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01089387 2025-12-04

INSTIN

Institut National de la Santé Et de la Recherche Médicale, France

Phase 1/2 Completed

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡